Aldeyra Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, ALDX, Aldeyra Therapeutics Inc, priceseries

Aldeyra Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.48
Close
3.75
High
3.80
Low
3.44
Previous Close
3.50
Daily Price Gain
0.25
YTD High
4.40
YTD High Date
Jan 4, 2022
YTD Low
3.00
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.52
YTD Gain
-12.18%
52 Week High
15.95
52 Week High Date
Apr 27, 2021
52 Week Low
3.00
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-6.91
52 Week Gain
-64.82%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 15. 2017
4.15
Jun 9. 2017
4.96
18 Trading Days
19.47%
Link
LONG
Sep 13. 2017
6.35
Sep 19. 2017
7.04
4 Trading Days
10.83%
Link
LONG
Apr 25. 2018
7.20
May 10. 2018
7.84
11 Trading Days
8.86%
Link
LONG
Sep 19. 2018
8.05
Oct 10. 2018
12.00
15 Trading Days
49.11%
Link
LONG
Dec 31. 2018
8.30
Jan 14. 2019
8.96
9 Trading Days
7.91%
Link
LONG
Aug 7. 2019
5.44
Aug 8. 2019
5.72
1 Trading Days
5.15%
Link
LONG
Dec 17. 2019
5.39
Dec 31. 2019
5.90
9 Trading Days
9.47%
Link
LONG
Apr 8. 2020
2.24
Apr 21. 2020
2.54
8 Trading Days
13.47%
Link
LONG
May 11. 2020
2.96
Jun 11. 2020
4.54
22 Trading Days
53.41%
Link
LONG
Jul 8. 2020
4.36
Jul 29. 2020
6.36
15 Trading Days
45.81%
Link
LONG
Jan 7. 2021
8.47
Jan 27. 2021
11.15
13 Trading Days
31.66%
Link
LONG
May 27. 2021
11.85
Jun 10. 2021
12.50
9 Trading Days
5.44%
Link
Company Information
Stock Symbol
ALDX
Exchange
NasdaqCM
Company URL
http://www.aldeyra.com
Company Phone
781-761-4904
CEO
Todd C. Brady
Headquarters
Massachusetts
Business Address
131 HARTWELL AVENUE, SUITE 320, LEXINGTON, MA 02421
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001341235
About

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Description

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. It is developing NS2, a small molecule designed to trap and allow for the degradation of aldehydes. Its product is used for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, sjogren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading